{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:00:35Z","timestamp":1792677635434,"version":"4.5.0"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"\n Importance<\/jats:title>\n Progression from acute urticaria (AU) to chronic urticaria (CU) occurs in a subset of patients, but consistent factors associated with progression remain unclear. Identifying patients at risk could inform follow-up strategies and therapeutic decisions; however, evidence on prognostic factors is heterogeneous and uncertain.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To systematically review clinical, laboratory, and treatment-related factors associated with progression from AU to CU.<\/jats:p>\n <\/jats:sec>\n \n Evidence Review<\/jats:title>\n A systematic search of MEDLINE, Embase, and Web of Science was conducted for English-language studies from database inception to December 31, 2025. Observational studies evaluating factors associated with chronicity in patients with AU were included. Paired reviewers independently screened studies, extracted data, and assessed risk of bias using an adapted Newcastle-Ottawa Scale and certainty of evidence using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. Due to heterogeneity, findings were synthesized qualitatively.<\/jats:p>\n <\/jats:sec>\n \n Findings<\/jats:title>\n Sixteen studies (52\u202f564 total patients; sample size range, 57 to 49\u202f129 patients) were included. Reported progression rates ranged from 5.8% to 36.0%, influenced by follow-up duration and outcome definitions, with higher rates potentially reflecting selection bias in tertiary centers. Clinical factors, such as disease severity, angioedema, allergic sensitization, and atopic status, showed inconsistent associations with chronicity. Laboratory markers, such as total immunoglobulin E, eosinophil counts, systemic inflammatory indices (including the neutrophil-to-lymphocyte ratio and systemic immune-inflammation index), and autoantibody profile, were not reproducibly associated with progression. Treatment-related factors, including the use of systemic corticosteroids during the acute phase, were not associated with reduced risk of progression. Overall, evidence quality was limited by methodologic heterogeneity, short follow-up, and moderate to high risk of bias.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This systematic review found that no single clinical or laboratory marker was consistently associated with progression from AU to CU, and current evidence does not support the use of aggressive treatment strategies during the acute phase solely to prevent chronicity. Careful clinical evaluation and structured follow-up remain essential, and emerging data on inflammatory and immunologic parameters may help identify subgroups at higher risk. These findings underscore the need for well-designed multicenter prospective studies with standardized outcome definitions and longer follow-up.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamadermatol.2026.1901","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T15:33:00Z","timestamp":1782315180000},"page":"824","source":"Crossref","is-referenced-by-count":1,"title":["Progression From Acute to Chronic Urticaria"],"prefix":"10.1001","volume":"162","author":[{"given":"Enrique","family":"G\u00f3mez de la Fuente","sequence":"first","affiliation":[{"name":"Department of Dermatology, Ram\u00f3n y Cajal University Hospital, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"Ortiz de Frutos","sequence":"additional","affiliation":[{"name":"Department of Dermatology, 12 de Octubre University Hospital, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelia","family":"\u00c1lvarez-D\u00edaz","sequence":"additional","affiliation":[{"name":"Medical Library, Ram\u00f3n y Cajal University Hospital, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Pindado-Ortega","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Ram\u00f3n y Cajal University Hospital, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Berna-Rico","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Ram\u00f3n y Cajal University Hospital, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"drv260002r1","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/all.15090","article-title":"The international EAACI\/GA2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria.","volume":"77","author":"Zuberbier","year":"2022","journal-title":"Allergy"},{"issue":"1","key":"drv260002r2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41572-022-00389-z","article-title":"Urticaria.","volume":"8","author":"Kolkhir","year":"2022","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"drv260002r3","first-page":"1","article-title":"Acute urticaria: etiologies, clinical course and quality of life.","volume":"26","author":"Kulthanan","year":"2008","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"71","key":"drv260002r4","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"9","key":"drv260002r6","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa Scale for the assessment of the quality of nonrandomized studies in meta-analyses.","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"issue":"3","key":"drv260002r7","doi-asserted-by":"publisher","DOI":"10.1111\/pai.70053","article-title":"Can urticaria severity be used as a biomarker for transition from acute to chronic urticaria?","volume":"36","author":"Yildirim","year":"2025","journal-title":"Pediatr Allergy Immunol"},{"issue":"12","key":"drv260002r8","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1159\/000538903","article-title":"Acute urticaria: symptoms, causes, and evaluation of phenotypes prone to chronicity.","volume":"185","author":"Gorgulu Akin","year":"2024","journal-title":"Int Arch Allergy Immunol"},{"issue":"2","key":"drv260002r9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1089\/ped.2024.0022","article-title":"Is it possible to use inflammatory markers as potential biomarkers for chronic urticaria?","volume":"37","author":"Kocatepe","year":"2024","journal-title":"Pediatr Allergy Immunol Pulmonol"},{"issue":"5","key":"drv260002r10","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.aller.2018.12.010","article-title":"Predictive factors for progression to chronicity or recurrence after the first attack of acute urticaria in preschool-age children.","volume":"47","author":"Cetinkaya","year":"2019","journal-title":"Allergol Immunopathol (Madr)"},{"issue":"3","key":"drv260002r11","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.alit.2016.12.007","article-title":"Analysis of primary treatment and prognosis of spontaneous urticaria.","volume":"66","author":"Tanaka","year":"2017","journal-title":"Allergol Int"},{"issue":"5","key":"drv260002r12","doi-asserted-by":"publisher","first-page":"394","DOI":"10.2500\/aap.2016.37.3971","article-title":"The clinical and laboratory characteristics of acute spontaneous urticaria and its progression to chronic spontaneous urticaria.","volume":"37","author":"Magen","year":"2016","journal-title":"Allergy Asthma Proc"},{"issue":"4","key":"drv260002r13","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.aller.2012.05.007","article-title":"The general characteristics of acute urticaria attacks and the factors predictive of progression to chronic urticaria.","volume":"41","author":"Comert","year":"2013","journal-title":"Allergol Immunopathol (Madr)"},{"issue":"1","key":"drv260002r14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jmii.2011.12.030","article-title":"Analysis of serum total IgE, specific IgE and eosinophils in children with acute and chronic urticaria.","volume":"46","author":"Chang","year":"2013","journal-title":"J Microbiol Immunol Infect"},{"issue":"5","key":"drv260002r15","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/1346-8138.14830","article-title":"Factors associated with relapses among patients treated for acute urticaria.","volume":"46","author":"Maillet","year":"2019","journal-title":"J Dermatol"},{"issue":"2","key":"drv260002r16","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1093\/bjd\/ljaf431","article-title":"Patients with acute and chronic spontaneous urticaria have similar autoantibody profiles: CHAPEAU pilot study.","volume":"194","author":"Bonnekoh","year":"2026","journal-title":"Br J Dermatol"},{"issue":"2","key":"drv260002r17","doi-asserted-by":"publisher","first-page":"80","DOI":"10.23822\/EurAnnACI.1764-1489.148","article-title":"Pediatric urticaria in the emergency department: epidemiological characteristics and predictive factors for its persistence in children.","volume":"53","author":"Talarico","year":"2021","journal-title":"Eur Ann Allergy Clin Immunol"},{"issue":"1","key":"drv260002r18","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.alit.2018.05.011","article-title":"Natural course of new-onset urticaria: results of a 10-year follow-up, nationwide, population-based study.","volume":"68","author":"Eun","year":"2019","journal-title":"Allergol Int"},{"issue":"1","key":"drv260002r19","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1159\/000534020","article-title":"Atopy does not influence the clinical outcome of acute urticaria: a retrospective study.","volume":"185","author":"Yang","year":"2024","journal-title":"Int Arch Allergy Immunol"},{"issue":"4","key":"drv260002r20","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/all.12335","article-title":"NSAID-induced urticaria\/angioedema does not evolve into chronic urticaria: a 12-year follow-up study.","volume":"69","author":"Do\u00f1a","year":"2014","journal-title":"Allergy"},{"issue":"3","key":"drv260002r21","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1001\/archderm.134.3.319","article-title":"Acute urticaria in infancy and early childhood: a prospective study.","volume":"134","author":"Mortureux","year":"1998","journal-title":"Arch Dermatol"},{"issue":"4","key":"drv260002r22","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2340\/0001555576295297","article-title":"Acute urticaria: clinical aspects and therapeutic responsiveness.","volume":"76","author":"Zuberbier","year":"1996","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"drv260002r23","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1111\/jdv.14221","article-title":"Factors linked to disease severity and time to remission in patients with chronic spontaneous urticaria.","volume":"31","author":"S\u00e1nchez-Borges","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"17","key":"drv260002r24","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1001\/jama.2024.15568","article-title":"Chronic spontaneous urticaria: a review.","volume":"332","author":"Kolkhir","year":"2024","journal-title":"JAMA"},{"issue":"11","key":"drv260002r25","doi-asserted-by":"publisher","first-page":"4138","DOI":"10.1016\/j.jaip.2021.07.043","article-title":"Autoimmune chronic spontaneous urticaria detection with IgG anti-TPO and total IgE.","volume":"9","author":"Kolkhir","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"11","key":"drv260002r26","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1111\/jdv.19904","article-title":"Treatment of acute urticaria: a systematic review.","volume":"38","author":"Badloe","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"drv260002r27","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/j.jaip.2024.04.016","article-title":"Efficacy and safety of systemic corticosteroids for urticaria: a systematic review and meta-analysis of randomized clinical trials.","volume":"12","author":"Chu","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"drv260002r28","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.jaip.2024.01.022","article-title":"Evaluation of pharmacological treatments for acute urticaria: a systematic review and meta-analysis.","volume":"12","author":"Jamjanya","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"drv260002r29","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-027431","article-title":"Glucocorticoids for acute urticaria: study protocol.","volume":"9","author":"Javaud","year":"2019","journal-title":"BMJ Open"},{"issue":"9","key":"drv260002r30","doi-asserted-by":"publisher","first-page":"3134","DOI":"10.3390\/jcm12093134","article-title":"Neuro-immuno-psychological aspects of chronic urticaria.","volume":"12","author":"Tomaszewska","year":"2023","journal-title":"J Clin Med"},{"issue":"5","key":"drv260002r31","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.clinthera.2020.03.010","article-title":"Psychological stress and chronic urticaria: a neuro-immuno-cutaneous crosstalk. A systematic review of the existing evidence.","volume":"42","author":"Konstantinou","year":"2020","journal-title":"Clin Ther"},{"key":"drv260002r5","unstructured":"Wells? GA, Shea? B, O\u2019Connell? D, . The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Ottawa Hospital Research Institute. Accessed April 28, 2026. https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2850207\/jamadermatology_gmez_de_la_fuente_2026_rv_260002_1786734776.08826.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T15:00:27Z","timestamp":1787151627000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2850207"}},"subtitle":["A Systematic Review"],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2026.1901","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,1]]}}}